Aveo Licenses Tricky Tivozanib To EUSA In Europe
This article was originally published in Scrip
Executive Summary
If Aveo Oncology's lead cancer drug candidate tivozanib was a cat, it would be on its eighth out of nine lives by now, the latest of which involves an ex-US partnership with EUSA Pharma that offers a small $2.5m upfront payment, but potentially lucrative milestone fees totaling as much as $394m.